Study of CT0991 for relapsed or refractory AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new treatment called CT0991 for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. It focuses on patients whose cancer cells show a high level of a protein called CD38.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your AML must have returned or not responded to previous treatments.
- Your cancer cells must test positive for CD38 protein at a level of 80% or higher.
- You must be in generally good health, with adequate heart, liver, and kidney function.
- You cannot have certain other types of leukemia, a history of seizures, or have had prior CAR-T therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment, CT1390B, for people whose acute myeloid leukemia (AML) has come back or not responded to other treatments. The goal is to see if it is safe and effective.
This trial tests an engineered immune cell treatment (CAR-T) made to target FLT3, for adults with acute myeloid leukemia (AML) that has come back or did not respond to standard treatment. It aims to control the leukemia when options have been limited.
This study tests a new CAR-T cell therapy that targets two proteins, CLL1 and CD38, on leukemia cells. It is designed for people whose acute myeloid leukemia has returned or not responded to treatment.
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
This trial tests a new cell therapy called A-CAR028 for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy uses your own immune cells to fight the cancer.
This trial tests a new type of immune cell therapy (CAR-T) that targets three proteins (CLL1, CD33, NKG2D) on leukemia cells in patients with acute myeloid leukemia that has not responded to or come back after prior treatment.
Hear when a new Relapsed/Refractory Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.